Isolation and Characterization of the Novel Botulinum Neurotoxin A Subtype 6

Molly S. Moritz, William H. Tepp, Marite Bradshaw, Eric A. Johnson, Sabine Pellett

ABSTRACT Botulinum neurotoxins (BoNTs), the most potent toxins known to humans and the causative agent of botulism, exert their effect by entering motor neurons and cleaving and inactivating SNARE proteins, which are essential for neurotransmitter release. BoNTs are proven, valuable pharmaceuticals used to treat more than 200 neuronal disorders. BoNTs comprise 7 serotypes and more than 40 isoforms (subtypes). BoNT/A1 is the only A-subtype used clinically due to its high potency and long duration of action. While other BoNT/A subtypes have been purified and described, only BoNT/A2 is being investigated as an alternative to BoNT/A1. Here we describe subtype BoNT/A6 with improved pharmacological properties compared to BoNT/A1. It was isolated from Clostridium botulinum CDC41370, which produces both BoNT/B2 and BoNT/A6. The gene encoding BoNT/B2 was genetically inactivated, and A6 was isolated to greater than 95% purity. A6 was highly potent in cultured primary rodent neuronal cultures and in human induced pluripotent stem cell-derived neurons, requiring 20-fold less toxin to cause 50% SNAP-25 cleavage than A1. Second, A6 entered hiPSCs faster and more efficiently than A1 and yet had a long duration of action similar to BoNT/A1. Third, BoNT/A6 had similar LD_{50} as BoNT/A1 after intraperitoneal injection in mice; however, local intramuscular injection resulted in less systemic toxicity than BoNT/A1 and a higher (i.m.) LD_{50}, indicating its potential as a safer pharmaceutical. These data suggest novel characteristics of BoNT/A6 and its potential as an improved pharmaceutical due to more efficient neuronal cell entry, greater ability to remain localized at the injection site, and a long duration.

IMPORTANCE Botulinum neurotoxins (BoNTs) have proved to be an effective treatment for a large number of neuropathic conditions. BoNTs comprise a large family of zinc metalloproteases, but BoNT/A1 is used nearly exclusively for pharmaceutical purposes. The genetic inactivation of a second BoNT gene in the native strain enabled expression and isolation of a single BoNT/A6 from cultures. Its characterization indicated that BoNT/A subtype A6 has a long duration of action comparable to A1, while it enters neurons faster and more efficiently and remains more localized after intramuscular injection. These characteristics of BoNT/A6 are of interest for potential use of BoNT/A6 as a novel BoNT-based therapeutic that is effective and has a fast onset, an improved safety profile, and a long duration of action. Use of BoNT/A6 as a pharmaceutical also has the potential to reveal novel treatment motifs compared to currently used treatments.

KEYWORDS BoNT, BoNT/A6, botulinum neurotoxin, cell entry, duration, potency, subtype

Botulinum neurotoxins (BoNTs) are the most poisonous toxins known to humans. BoNTs are designated Tier 1 Select Agents, and their production, isolation, and characterization require CDC-approved laboratory facilities. They are produced by Clostridium botulinum and select strains of Clostridium butyricum, Clostridium sporogenes.
genes, Clostridium argentinense, and Clostridium baratii (1, 2). They comprise seven immunologically distinct BoNTs (A to G) and at least 40 isoforms (subtypes). BoNTs are synthesized as 150-kDa dichain proteins comprised of a 100-kDa heavy chain (HC) and a 50-kDa light chain (LC) linked by a disulfide bond. The HC has a C-terminal domain (HC), which recognizes and binds to gangliosides and protein receptors on neuronal cells, and an N-terminal domain (HN), which functions in translocation of the LC into the cell cytosol (3–5). Once inside the cell, the LC specifically cleaves a soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) protein, thereby inactivating neurotransmitter release (6, 7). This leads to the characteristic flaccid paralysis of botulism, which can last several days to months depending on BoNT sero- and subtype and the dose. The long duration of action is due to the persistence and continued catalytic activity of the LC inside neurons (8). While BoNTs have the potential to cause serious illness, they are used in the effective treatment of a myriad of neuronal disorders, providing therapy to numerous diseases, many of which were previously untreatable (9).

BoNTs are divided into seven serotypes (A to G) which are further categorized into subtypes based on variations in amino acid sequences (1, 10–13). Despite the multitude of BoNT subtypes, only two are being employed as pharmaceuticals, namely, BoNT/A1 and to a much lesser extent BoNT/B1. This is in part due to the unavailability of the purified BoNT subtypes, and a corresponding dearth of knowledge of pharmaceutical properties of most BoNT subtypes. Only a few BoNT subtypes have been isolated and characterized for their biochemical, cellular, and in vivo properties. Most research has focused on BoNT/A subtypes. In vitro and in vivo investigations of BoNT/A subtypes 1 to 5 isolated in our and other laboratories have revealed unique properties of some subtypes, including potency, cell entry kinetics, duration of action, and cellular mechanisms governing these properties (13–16). In an earlier study in our laboratory, BoNT/A2 was shown to enter neuronal cells faster and more efficiently than BoNT/A1 (15, 16). In vivo studies in mice comparing purified BoNT/A1 and A2 indicated similar potency and duration of action and a slightly faster onset of local paralysis by A2 (17). A further study compared a pharmaceutical preparation of purified BoNT/A2 with pharmaceutically formulated BoNT/A1 complex in mice after local intramuscular injection. This study indicated that the A2 product was more potent than the A1 product for causing local paralysis and remained more localized within the injection site, suggesting a lower risk for detrimental side effects (18–20). As a result of these data, BoNT/A2 was suggested as another subtype of choice for therapeutic treatment (18, 19) and is currently in clinical trials in Japan (20).

In addition to the biochemical and functional characterizations of BoNT/A1 to -5, BoNT/A subtypes A7 and A8 have recently been partially characterized in vitro (21, 22). However, for subtype BoNT/A6 little is known of its composition and functional properties, largely because BoNT/A6 is produced in a strain that produced two BoNTs, B2 and A6 (23, 24). This complicates its isolation and characterization. BoNT/A6 differs from other BoNT/A subtypes in its amino acid sequence by 4% to 14%, with the greatest similarity to A1 (95.7%) and A5 (95.9%) and the greatest dissimilarity to A3 (86%) (23, 25). BoNT/A6 was first described in 2009 as a unique BoNT/A subtype, possibly derived from a recombination event of BoNT/A1 and A2 (23). The LC sequence of BoNT/A6 differs from that of A1 by only 1 amino acid residue outside any exosite region (T414A), while the translocation and receptor binding domains differ by 4.5 and 9.5%, respectively. The majority of the differences of the A6 translocation domain from A1 are also present in A2, but the receptor binding domain of A6 has several unique amino acid variations (see Fig. S1 in the supplemental material).

This study describes the isolation of BoNT/A6 and its characterization both in vitro and in vivo. The results show higher potency and faster cell entry kinetics of BoNT/A6 in cultured neuronal cell models compared to other BoNT/A subtypes, with similarities to A2 (16). Mouse studies indicate a faster onset and a long duration of action after local intramuscular injection comparable to BoNT/A1. These results indicate novel funda-
mental pharmacological properties of BoNT/A6 and its potential as an improved pharmaceutical.

RESULTS

BoNT/A6 was independently expressed and purified from its native strain. To facilitate purification and characterization of BoNT/A6 from its native dual-toxin-producing C. botulinum strain CDC41370, production of BoNT/B2 in this strain was genetically eliminated by inactivation of the B2 toxin gene using ClosTron mutagenesis system as previously described for C. botulinum strain 69016 producing BoNT/B2 and BoNT/FA (see Fig. S2A in the supplemental material) (24). Inactivation of the BoNT/B2 gene was confirmed by PCR (Fig. S2B), sequencing, and Southern hybridization (Fig. S2C to E). The mutant strain contained one copy of the intron element inserted into the targeted position in the bont/B2. The mutant strain was designated CDC41370/B2tox-. Western blot analysis of the wild-type and the mutant strain cultures with anti-BoNT/A1 antibodies revealed expression of the 150-kDa BoNT/A6, which was proteolytically activated to a 50-kDa light chain (LC) and a 100-kDa heavy chain (HC) in the culture. Western blotting using anti-BoNT/B1 antibodies, which strongly recognize BoNT/B (Fig. S3). These data confirmed that the CDC41370/B2tox- strain produced BoNT/A6 but not BoNT/B2 at levels detectable by immunoblotting.

Strain CDC41370/B2tox- was used to produce purified BoNT/A6 using previously described methods (15, 26, 27). A 10-liter starting culture resulted in a final yield of 9.5 mg of BoNT/A6 as determined by spectroscopy and SDS-PAGE gel analysis (Fig. 1). This is a similar yield from purification of an A1 Hall strain culture, which generally yields ~10 to 15 mg of purified BoNT/A1. Densitometry analysis of an SDS-PAGE gel indicated that the isolated BoNT/A6 was ~95% pure and was fully nicked to its dichain form (Fig. 1). A standard mouse bioassay was used to determine the specific activity of BoNT/A6. Deaths of mice were recorded through 4 days postinjection, and any mice that survived 48 h without botulism symptoms and appeared healthy were euthanized after 4 days. The LD50 was estimated to be 5.3 pg. This value is defined as 1 unit for this specific stock of BoNT/A6.

The catalytic LC of BoNT/A6 has similar activity as BoNT/A1 LC. Enzymatic activities of the light chains of BoNT/A1 and A6 were examined by FRET assay using a SNAP-25 fragment (aa141 to aa206) surrounded by a cyan fluorescent protein (CFP) and a yellow fluorescent protein (YFP) (BoTest; Biosentinel). As expected based on the almost 100% amino acid identity of these two LCs, there was no significant difference between the activities of LC/A1 and LC/A6 after 2 h (Fig. 2). The 50% effective concen-
Enzymatic Activity of LC of A1 and A6

![Graph showing enzymatic activity of LC of A1 and A6.](image)

**FIG 2** LC activity of BoNT/A1 and /A6 after 2 h. Serial dilutions of BoNT/A1 and /A6 were analyzed for light chain activity using a FRET endopeptidase assay (BoTest, Biosentinel). Proteolytic activity of BoNT/A in real time was detected using 3 independent experiments, and averages and standard deviations from the three independent assays are shown. The BoTest uses a truncated SNAP-25 reporter construct of amino acids 141 to 206 flanked by a cyan fluorescent protein (CFP) and a yellow fluorescent protein (YFP), which leads to fluorescence emissions reflecting cleavage of SNAP-25.

**FIG 3** SNAP-25 cleavage of BoNT/A1 and /A6 in hiPSCs. hiPSCs were exposed to serial dilutions of either A1 or A6 for 48 h. Cell lysates were analyzed for cleaved and uncleaved SNAP-25 by Western blotting and densitometry. Averages and standard deviations of triplicate samples are shown. The EC50 were determined in PRISM6 software using a nonlinear regression (four parameters).

**Table:**

|   | A1   | A6   |
|---|------|------|
| EC50 | 0.09156 | 0.1533 |

**Enzymatic Activity of LC of A1 and A6**

Enzymatic activity was determined to be 0.09 pM (95% confidence interval: 0.07 to 0.12) for A1 and 0.15 pM (95% confidence interval: 0.12 to 0.2) for A6 by analyzing the averages and standard deviations of each toxin concentration from the three independent assays. Similar data were observed with longer (up to 21 h) incubations (data not shown).

**BoNT/A6 has a high potency in neuronal cells.** Previous studies have described the potency of BoNT/A subtypes 1 through 5 in various cell models (15, 16). Exposure of cultured mouse and rat primary spinal cord cells (MSC and RSC cells) to serial dilutions of BoNT/A6 resulted in a SNAP-25 cleavage pattern similar to that previously observed for BoNT/A2, with 50% SNAP-25 cleavage occurring at $\sim 0.03$ U/50 $\mu$L/well (27 fM) after 48 h of toxin exposure (Fig. S4). The EC50 of BoNT/A6 was also determined in human iPSC-derived neurons. As with other BoNT/A subtypes, exposure of hiPSC neurons resulted in a steep dose-response curve extending from 0% to 100% cleavage within less than 4 logs for cells exposed to toxin for 48 h. The EC50 was calculated to be $\sim 0.03$ U/50 $\mu$L/well (Fig. 3), which is about 20-fold more sensitive than was seen in a parallel experiment for BoNT/A1 (0.6 U/50 $\mu$L/well). These data indicate that BoNT/A6 is significantly more potent in cultured neurons than BoNT/A1, especially in human neurons.
BoNT/A6 enters cells more efficiently than other BoNT/A subtypes. To examine the cell entry kinetics of BoNT/A6 compared to subtypes BoNT/A1 and A2, hiPSC-derived neurons were exposed to 67 pM of each of the toxins (Fig. 4). Cells were harvested at the indicated time points through 10 h postexposure. Lysates were examined for the amount of cleaved and uncleaved SNAP-25 by Western blotting and densitometry. The onset of SNAP-25 cleavage occurred more rapidly in cells exposed to BoNT/A6 and BoNT/A2 than BoNT/A1 (Fig. 4). Cells exposed to BoNT/A6 also experienced an average of 94% ± 5.3% SNAP-25 cleavage at the final 10-hour time point, while cells exposed to BoNT/A1 and A2 reached approximately 64% ± 4% and 84% ± 1.2% cleavage, respectively. While equimolar amounts of toxin were used in this assay, the three toxins had similar specific activities (5.6 pg/LD50 for A1, 4.9 pg/LD50 for A2, and 5.3 pg/LD50 for A6); thus, the results also compared similar numbers of biologically active units. This indicates that BoNT/A6 has an earlier onset of activity in cultured neurons compared to BoNT/A1 and similar to or even faster than BoNT/A2. Since catalytic activities of the BoNT/A6 and A1 LCs are similar, the earlier onset of activity in cultured neurons is likely due to faster or more efficient cell entry.

BoNT/A6 has a similarly long persistence of activity in cultured rat and human neurons as BoNT/A1. A previous report has shown that LC activities of BoNT/A1, A2, A4, and A5 persist in cultured primary rat spinal cord neurons for over 10 months, and that the recovery rate for uncleaved SNAP-25 in the intoxicated cells is steady but very low, reaching less than 50% after 10 months (28). To determine the duration of action of BoNT/A6 in cultured primary rodent neurons, primary rat spinal cord (RSC) cells, recovery from SNAP-25 cleavage after a pulse of toxin exposure was monitored over 8 months. Up to 6 months, only the BoNT/A cleavage product of SNAP-25 was detected by Western blotting. At 7 months after initial toxin exposure, about 90% of the detected SNAP-25 was cleaved and about 10% uncleaved, indicating beginning of recovery of the cells. After 8 months, about 79% of SNAP-25 remained cleaved (Fig. 5D). Although signs of SNAP-25 recovery were not seen until later compared to previous work on BoNT/A subtypes 1 to 5, the estimated slope of the line when signs of uncleaved SNAP-25 began was similar to that of BoNT/A1, A2, A4, and A5 previously observed, indicating similar persistence of LC activity within cultured neuronal cells (28).

Persistence of BoNT LC activity in human iPSC-derived neurons has previously been shown to be shorter than in primary rat spinal cord neurons, with dose-dependent recovery of the neurons within 3 to 5 months (16, 28). This allowed for estimation of the half-life of activity in human neurons by exposing the neurons to serial dilutions of either BoNT/A1 or BoNT/A6 and determining the EC50 at different time points post-toxin exposure. Western blotting and densitometry analyses of triplicate sets of cells with each dilution series harvested at days 3, 39, and 70 post-BoNT exposure resulted in EC50 values for BoNT/A6 of ~0.04 U/50 μl/well (day 3), 0.8 U/50 μl/well (day 39), and 1 U/50 μl/well (day 70) (or 28, 495, and 707 fm, respectively). EC50 values of BoNT/A1 were ~0.42 U/50 μl/well (day 3), 4.0 U/50 μl/well (day 39), and 17 U/50 μl/well (day 70).
The half-life of activity of BoNT/A1 and /A6 in these hiPSC-derived neurons was estimated from the EC50 values over time and was similar for both BoNT/A1 and /A6, at approximately 12 days and 14 days, respectively (Fig. 5C). Taken together, these results indicate that the BoNT/A6 LC persists and is enzymatically active in neurons for a similarly long time as BoNT/A1 LCs.

Onset and duration of action of BoNT/A6 is similar to BoNT/A1 in mice. To determine the onset and duration of action of BoNT/A6 compared to BoNT/A1, mice were injected with dilutions of either BoNT ranging from 0.2 to 0.6 U into the right hind gastrocnemius muscle. DAS scores (to measure local paralysis) and Rotarod times (to measure overall motor neuron deficiency) were recorded for each mouse at several time points throughout the first 48 h and then once each day through 16 days postinjection. The injected doses of each toxin were confirmed by IP LD50 assay using the same dilutions (data not shown). As previously seen for other BoNTs, the DAS scores and Rotarod recovery times were both dose dependent (Fig. 6). The peak DAS score appeared between 36 and 48 h, and it started to decrease at day 3 to 4, similar to previous reports for BoNT/A2 and slightly earlier than BoNT/A1 (Fig. 6A). By day 16, the DAS score had dropped to ~1.5 for mice injected with the highest toxin dilution (Fig. 6A), which is similar as previously observed with BoNT/A1, /A2, and /A5 (17).

Overall motor neuron deficiency, as measured by Rotarod, was similar for both BoNT/A1 and /A6 (Fig. 6B) and similar to that previously observed for other BoNT/A subtypes (17). These data indicate similar onset and duration of action of BoNT/A6 compared to
BoNT/A1 for local paralysis in mice after local intramuscular injection, in addition to similar overall motor neuron deficiency.

**BoNT/A6 remains more localized at the injection site after local intramuscular injection.** BoNT/A2, which enters cultured neuronal cells faster and more efficiently, similar to BoNT/A6, has previously been suggested to remain more localized after intramuscular injection into rodent gastrocnemius muscle than BoNT/A1 (15, 19). To determine if the faster cell entry of BoNT/A6 also leads to less toxin spread away from the injection site after local intramuscular injection, a relative IM LD50 (relative to the IP LD50 of the same toxin dilutions) in mice was determined for injection of BoNT/A1, /A2, and /A6 into the right gastrocnemius muscle. Toxin dilutions of each BoNT/A subtype were injected either intraperitoneally or intramuscularly in parallel, and mice were scored for survival. Most mice injected with lethal doses IP were found dead the day after injection, with a few dead at 2 days postinjection. However, the mice injected with lethal doses IM died slower, with deaths still occurring over a wide range of time postinjection. Using the Reed and Muench calculation methods, the LD50 values were calculated to be 5.6, 4.9, and 5.3 pg for the mice injected IP and 7.9, 9.9, and 10.6 pg for mice injected IM with BoNT/A1, /A2, and /A6, respectively. Thus, the IM LD50 for BoNT/A2 and BoNT/A6 both was ~2 IP LD50 units whereas the IM LD50 for BoNT/A1 was ~1.4 IP units (Table 1).

**DISCUSSION**

BoNT/A6 is naturally expressed in a dual-toxin-producing strain, CDC41370, isolated from a food-borne botulism case in 1996 (23). In addition to BoNT/A6, this strain also

| BoNT subtype | IP LD50 (pg) | IM LD50 (pg) | IM LD50 (U) |
|--------------|--------------|--------------|--------------|
| A1           | 5.6          | 7.9          | 1.4          |
| A2           | 4.9          | 9.9          | 2.0          |
| A6           | 5.3          | 10.6         | 2.0          |
expresses BoNT/B2, complicating the isolation and characterization of the BoNT/A6 toxin. As has been previously accomplished for the isolation of BoNT/FA from a bivalent strain (24), strain CDC41370 was modified to eliminate expression of BoNT/B2. BoNT/A6 was expressed at high levels in the resulting strain CDC41370B2lox−, and purification using standard protocols existing for other BoNT/A subtypes resulted in isolation of an ≥95% pure BoNT/A6. As has been previously observed for BoNT/A2, BoNT/A6 had a specific activity similar to BoNT/A1 when injected IP in mice but had about 20-fold higher potency in all tested cell models, including primary rat and mouse spinal cord cultures and hiPSC-derived neurons (Fig. 3). BoNT/A6 had similar in vitro LC enzymatic activity as BoNT/A1 in the BoTest but showed significantly faster SNAP-25 cleavage in cultured neurons (Fig. 2 and 4). This earlier onset of intracellular SNAP-25 cleavage combined with similar enzymatic activity of the LC indicates faster cell entry by BoNT/A6 than BoNT/A1 and similar entry to that previously observed for BoNT/A2 (5, 20). These data are consistent with the previous observation that BoNT/A6 may be derived from a genetic recombination event of BoNT/A2 and other BoNT/A subtypes (23) and indicate that there may be common amino acid sequence and structural elements in the HC of BoNT/A6 and /A2 underlying the faster cell entry kinetics.

We have previously observed that BoNT/A3 has a significantly shorter duration of action than BoNT/A1. The duration of action of BoNT/A6 was examined both in cultured neurons and in mice as previously performed for other BoNT/A subtypes (17, 28). Both the cell culture and in vivo mouse data indicate similar duration of action of BoNT/A6 and /A1 (Fig. 5 and 6) (17, 28). Interestingly, while persistence of BoNT/A1 and /A6 LC activity in cultured primary rodent neurons was very long, with only about 50% recovery after 10 months (Fig. 5D) (28), persistence of BoNT LC activity in cultured human iPSC-derived neurons was much shorter, with dose-dependent recovery of the neurons within 3 to 5 months, as has previously been shown for other BoNTs (16). This recovery time is similar to the recovery of paralysis of human muscle after local injection with pharmaceutical BoNT/A1. While the reasons for the difference in recovery time between the two cell models are not known, likely explanations include differences in differentiation stages of the cell models, differences in cell composition (>98% pure forebrain-like neurons versus a mixture of spinal cord neurons and glial cells), and the presence of glial cells in the primary neurons versus the pure neuronal population of the hiPSC-derived neurons. Furthermore, the different BoNTs may show different persistence because of different reactivities or mechanisms of BoNT degradation in cells such as ubiquitin-mediated protein degradation. Regardless of the underlying mechanism, this shorter recovery time enabled the estimation of the half-lives of BoNT/A1 and /A6 in human neurons, with the data indicating similar half-lives of ~12 and ~14 days for A1 and A6, respectively (Fig. 5C), which is consistent with a similar duration of action in primary rat spinal cord cells and in mice. Together, these data demonstrate a similar duration of action of BoNT/A6 and BoNT/A1, which is consistent with the high degree of amino acid identity of the A6 and A1 LCs, which differ by only one residue (T414A).

Faster cell entry of BoNT/A2 has been suggested to correlate with faster onset of local paralysis after intramuscular injection (15, 17–20). Similar to what was previously observed for BoNT/A2, the onset of local paralysis as measured by DAS appeared slightly earlier for BoNT/A6 than for BoNT/A1 (Fig. 6A), although these observational data rely on qualitative and relatively small differences and will need to be confirmed in larger animals or in a clinical setting. Mice are relatively small animals compared to humans and other animals such as wildlife showing botulism in nature. Therefore, mice and other small animal models require local BoNT doses relatively close to lethal doses for observation of significant local paralysis (0.2 to 0.75 U), with 1 to 2 units being lethal after IM injection (Table 1). Due to the resulting relatively small effective dose range in mice, it may be difficult to quantitatively discern differences in the dose-dependent onset of paralysis time. For botulism in larger animals or in pharmaceutical treatments of humans, smaller relative doses can be injected locally and lead to paralysis, likely due to the larger size of the injected muscle and whole organisms being less prone to systemic distribution of toxin. Therefore, future studies in larger animals or clinical
studies will be required to definitively determine whether BoNT/A6 and BoNT/A2 result in a significantly faster onset of pharmaceutical action than BoNT/A1.

The faster and more efficient cell entry and possibly faster onset of action by BoNT/A6 and /A2 than BoNT/A1 raise the questions whether BoNT/A6 and /A2 have the potential to remain more localized within the injection site after in vivo intramuscular injection, which would result in fewer side effects during pharmaceutical use due to toxin spread away from the injection site. In vivo studies in mice comparing a pharmaceutical preparation of purified BoNT/A2 (with the excipients unknown) to pharmaceutical BoNT/A1 complex indicated a significant difference in the IM LD$_{50}$ for the two toxins (19). Here, we directly compared purified preparations of BoNT/A1, /A2, and /A6 for their lethality in mice after intraperitoneal and intramuscular injection. Importantly, for each subtype the same toxin dilutions and relative concentrations of active BoNT were used for the IM and IP injections, enabling determination of a relative IM LD$_{50}$ dose for each toxin. Based on the calculated LD$_{50}$ determined from a standard MBA with IP injections, IM injections of BoNT/A6 and BoNT/A2 required 2.0 times as much toxin to be lethal as the amount of toxin injected IP, while BoNT/A1 required only 1.4 times as much toxin (Table 1). These data support the previous observation that BoNT/A2 remains more localized after intramuscular injection than BoNT/A1 and indicate that, similar to BoNT/A2, BoNT/A6 also results in less systemic toxin distribution than for BoNT/A1 (19).

Taken together, our results demonstrate several properties of BoNT/A6 that would be beneficial if used as a new BoNT-based pharmaceutical, including faster and more efficient neuronal cell entry than BoNT/A1, similarly long duration of action, and less systemic spread after local injection. Treatments with BoNT/A6 may relieve targeted symptoms faster with fewer risks for side effects and without compromising the long-lasting duration. This study is based on one batch of purified BoNT/A6, and future work with additional batches and pharmacologic preparations of BoNT/A6 will be required to assess safety and effectiveness of BoNT/A6 as a new pharmaceutical. These studies showing different phenotypes in cells and animals for subtypes also provide biological systems for understanding the molecular, cellular, and organismal basis for these different and important properties of BoNTs.

MATERIALS AND METHODS

Biosafety, biosecurity, and ethics. The Johnson laboratory and personnel are registered with the Federal Select Agent Program for research involving botulinum neurotoxins (BoNTs) and BoNT-producing strains of clostridia. The research program, procedures, documentation, security, and facilities are closely monitored by the University of Wisconsin-Madison Biosafety Task Force, the University of Wisconsin-Madison Office of Biological Safety, the University of Wisconsin-Madison Select Agent Program, and the Centers for Disease Control and Prevention (CDC) as part of the University of Wisconsin-Madison Select Agent Program. All personnel have undergone suitability assessments and completed rigorous and continuing biosafety training, including biosafety level 3 (BSL3) and BSL2 and select agent practices, before participating in laboratory studies involving BoNTs and neurotoxigenic C. botulinum. All animal experiments were approved by and conducted according to guidelines of the University of Wisconsin Animal Care and Use Committee.

Construction of a BoNT/B2 insertional mutant from the native BoNT/A6-producing C. botulinum strain. Strain CDC41370 expresses both BoNT/B2 and BoNT/A6 (23). The production of two BoNTs complicates the isolation of pure BoNT/A6. The gene encoding botulinum neurotoxin B2 (GenBank accession number FJ981697) in C. botulinum strain CDC41370 was inactivated with a Clostron mutagenesis system by insertion of a mobile group II intron between nucleotides 381 and 382 on a sense strand using plasmid pMTL007C-E2:Cloclontvbb-381s as previously described for inactivation of the BoNT/B2 gene in C. botulinum strain CDC69016 (15, 24–27, 29). Inactivation of the BoNT/B2 gene was confirmed by PCR, DNA sequencing, and Southern hybridization as previously described using the same primers and probes (24). This resulted in strain CDC41370B2mut, which expressed exclusively BoNT/A6 at high levels. BoNT/A6 (~150-kDa protein) was then purified from this modified strain, yielding highly pure toxin using the method previously described to produce BoNT/FA (15, 26, 27).

Botulinum neurotoxins. BoNT/A1 and /A2 were independently purified (~150-kDa proteins) from C. botulinum strains Hall A-hyper and Kyoto-F as previously described (15, 26, 27). The purity of the toxins was confirmed by spectroscopy and SDS-PAGE. The purified toxins were stored in 0.1 M sodium phosphate buffer, pH 7, with 40% glycerol at −20°C until use. Specific activities of each subtype preparation were determined using an intraperitoneal mouse bioassay (MBA) as previously described (30–33). The specific activities of the BoNTs in mice were 5.6 pg/LD$_{50}$ (A1), 4.9 pg/LD$_{50}$ (A2), and...
5.3 pg/LD\textsubscript{50} (A6). Protein concentrations of purified BoNT/A1, /A2, and /A6 were determined by measuring the absorbance at A\textsubscript{280} and an extinction coefficient of 1.63 and by SDS-PAGE gel analysis.

**BoNTase** The proteinase K (BoNTase) fragment-leaving BoTest for A/E BoNTs (Biosentinel Pharmaceuticals) was used according to the manufacturer's instructions. Tenfold serial dilutions of BoNT/A1 and /A6 were prepared in 1× reaction buffer solution containing 5 mM dithiothreitol (DTT) (Sigma) for toxin reduction. The data presented are the average from the results from three independent experiments performed on each subtype, each of which included a control without BoNT present. The plate was incubated at 30°C for 2 h, and emission ratios were determined after addition of reporter to the BoNT dilutions. A BioTek Synergy H1 Hybrid reader recorded the absorbance of each well. The 50% effective concentration (EC\textsubscript{50}) was determined by analyzing the averages and standard deviations for each concentration from the three independent assays using a nonlinear regression (four parameters) in PRISM 6.

**Primary rat (RSC) and mouse spinal cord (MSC) cell assay.** Primary rat and mouse spinal cord cells were prepared as previously described (28, 34). The cells were plated on a 96-well, flat-bottom plate (Techno Plastic Products [TPP]) plate treated with 0.01% poly-L-ornithine (Sigma) and coated with 8.3 μg/cm\textsuperscript{2} growth factor-reduced Matrigel (BD Biosciences). The cells were maintained in culture medium (CM) (Neurobasal medium supplemented with B27, GlutaMAX, and penicillin/streptomycin [Life Technologies]) and allowed to mature for a minimum of 2 weeks. Cells were exposed to BoNT in 50 μl per well and incubated at 37°C in a 5% CO\textsubscript{2} humidified atmosphere for the indicated amount of time. Cells were lysed in 75 μl of 1× LDS lysis buffer and analyzed by Western blotting.

To determine the EC\textsubscript{50}, MSCs and RSCs were exposed to serial (3-fold) dilutions of BoNT in CM. Experiments were performed in at least triplicate, and a no-toxin control was included in each replicate. BoNT dilutions remained on cells for 48 h at 37°C in a 5% CO\textsubscript{2} humidified atmosphere. BoNT was then removed, cells were lysed in 75 μl of 1× LDS lysis buffer (Life Technologies), and cell lysates were analyzed for the presence of cleaved and uncleaved SNAP-25 by Western blotting and densitometry.

**Human iPSC-derived neuron cell assay.** iPSCs were differentiated into neurons using a three-step differentiation protocol resulting in fully matured neurons, as described previously (28). Cells were plated at 5000 cells/well in a 96-well flat-bottom plate in Neurobasal medium supplemented with B27, GlutaMAX, and penicillin/streptomycin (Life Technologies). Cells were maintained in culture medium for the indicated amount of time.

**Western blot analysis.** Western blot analyses were carried out as previously described (28, 34). All cell lysates were separated on 12% Novex NuPAGE gels (Life Technologies) using MES running buffer (Invitrogen) and transferred onto a 0.45-μm PVDF membrane (Millipore). Membranes were incubated in blocking buffer for 30 min and then in anti-SNAP-25 (Synaptic Systems) primary antibody solution overnight. After five 5-min washes with washing buffer (KPL), the membranes were rinsed with ddH\textsubscript{2}O and incubated in secondary anti-mouse antibody (KPL) for one hour. Five additional washes with washing buffer were done, and membranes were rinsed with ddH\textsubscript{2}O and incubated in chemiluminescent substrate (Phosphaglo, KPL) for 3 min. Images of bands on membranes were obtained using a Fotodyne FOTO/Analyst FX imager and analyzed by densitometry with TotalLab Quant and PRISM 6 software (GraphPad Software Inc.).

**Onset and duration of action in vivo.** Onset and duration of action were determined in vivo as previously described (17). Using a 0.3 ml insulin syringe with 5-μl markings, groups of 5 female ICR mice were injected with the indicated concentrations of BoNT/A1 or BoNT/A6 in 10 μl 0.9% saline. The cells were harvested at 3 days after initial BoNT exposure and monthly thereafter until 8 months postexposure. All time points were tested in quadruplicate and included no-toxin controls. Cleaved and uncleaved SNAP-25 was monitored over time by Western blotting and densitometry.

**Human iPSC-derived neuron cell assay.** iPSC GABA Neurons (Cellular Dynamics) were stored in liquid nitrogen until use. The cells were plated on a TPP, 96-well, flat-bottom plate treated with 0.01% poly-L-ornithine and 8.3 μg/cm\textsuperscript{2} Matrigel coated. The cells were maintained in iCell Neuron maintenance medium (Life Technologies) and matured for about 1 week until toxin exposure.

To determine the EC\textsubscript{50}, the cells were exposed to serial (3-fold) dilutions of BoNT in CM. Experiments were performed at least triplicate, and a no-toxin control was included in each replicate. BoNT dilutions remained on cells for 48 h at 37°C in a 5% CO\textsubscript{2} humidified atmosphere. BoNT was then removed, cells were lysed in 50 μl of 1× LDS lysis buffer, and cell lysates were analyzed for the presence of cleaved and uncleaved SNAP-25 by Western blotting and densitometry.

To determine the duration of action of BoNT/A6 in primary neuronal cells, RSCs were exposed to equal molarity (67 nM) of BoNT/A6 and BoNT/A6, which is the minimum required to achieve 100% SNAP-25 cleavage in RSCs. Extracellular BoNT was removed by washing the cells in 0.3 ml of CM three times, and cells were further incubated in culture medium without BoNT as previously described for other BoNT/A subtypes (28). Cells were harvested at 3 days after initial BoNT exposure and monthly thereafter until 8 months postexposure. All time points were tested in quadruplicate and included no-toxin controls. Cleaved and uncleaved SNAP-25 was monitored over time by Western blotting and densitometry.

**Western blot analysis.** Western blot analyses were carried out as previously described (28, 34). All cell lysates were separated on 12% Novex NUPage gels (Life Technologies) using MES running buffer (Invitrogen) and transferred onto a 0.45-μm PVDF membrane (Millipore). Membranes were incubated in blocking buffer for 30 min and then in anti-SNAP-25 (Synaptic Systems) primary antibody solution overnight. After five 5-min washes with washing buffer (KPL), the membranes were rinsed with ddH\textsubscript{2}O and incubated in secondary anti-mouse antibody (KPL) for one hour. Five additional washes with washing buffer were done, and membranes were rinsed with ddH\textsubscript{2}O and incubated in chemiluminescent substrate (Phosphaglo, KPL) for 3 min. Images of bands on membranes were obtained using a Fotodyne FOTO/Analyst FX imager and analyzed by densitometry with TotalLab Quant and PRISM 6 software (GraphPad Software Inc.).

**Onset and duration of action in vivo.** Onset and duration of action were determined in vivo as previously described (17). Using a 0.3 ml insulin syringe with 5-μl markings, groups of 5 female ICR mice were injected with the indicated concentrations of BoNT/A1 or BoNT/A6 in 10 μl 0.9% saline. The cells were harvested at 3 days after initial BoNT exposure and monthly thereafter until 8 months postexposure. All time points were tested in quadruplicate and included no-toxin controls. Cleaved and uncleaved SNAP-25 was monitored over time by Western blotting and densitometry.
attempted to run for a total of 5 min while the Rotarod increased in speed from 4 to 40 rpm. Rotarod analysis was ceased for a group once all mice ran the full 5 min 2 times consecutively.

**Determination of intramuscular LD₅₀ in mice.** Groups of 10 female ICR mice (Harlan) were injected with the indicated amounts of BoNT/A₁, A₂, or A₆ in 10 μl GelPhos buffer using a 0.3-ml insulin syringe (BD) into the right gastrocnemius muscle. In parallel, groups of 5 mice received intraperitoneal injections of the same BoNT dilutions in 0.5 ml GelPhos buffer using a 0.5-ml insulin syringe (BD). Mice were observed through 6 days postinjection, and any deaths were recorded. The LD₅₀ in pg was calculated for both the intramuscularly (IM) and intraperitoneally (IP) injected mice using the Reed and Muench method (35). Based on the IP data and a unit definition of 1 unit = the amount of BoNT required to result in death of 50% of mice after IP injection within 4 days, the specific activity of each BoNT was determined in units (IP LD₅₀) for the toxin dilutions used in this comparative assay. The IM LD₅₀ in units was calculated based on the IP LD₅₀ values.

**SUPPLEMENTAL MATERIAL**

Supplemental material for this article may be found at https://doi.org/10.1128/mSphere.00466-18.

- FIG S1, PDF file, 0.03 MB.
- FIG S2, TIF file, 0.8 MB.
- FIG S3, TIF file, 0.9 MB.
- FIG S4, TIF file, 0.2 MB.

**ACKNOWLEDGMENTS**

This work was supported by the University of Wisconsin-Madison and the National Institutes of Health (R01 AI095274, R56 AI095274). We thank the Centers for Disease Control for providing our lab with strain CDC41370.

**REFERENCES**

1. Hill KK, Smith TJ. 2013. Genetic diversity within *Clostridium botulinum* serotypes, botulinum neurotoxin gene clusters and toxin subtypes. Curr Top Microbiol Immunol 364:1–20. https://doi.org/10.1007/978-3-642-33570-9_1.

2. Johnson EA, Montecucco C. 2008. Botulism. Handb Clin Neurol 91:333–368. https://doi.org/10.1016/S0072-9752(07)91511-4.

3. Montal M. 2010. Botulinum neurotoxin: a marvel of protein design. Annu Rev Biochem 79:591–617. https://doi.org/10.1146/annurev.biochem.051908.125345.

4. Rummel A. 2015. The long journey of botulinum neurotoxins into the nervous system. Toxicon 107:9–24. https://doi.org/10.1016/j.toxicon.2015.09.009.

5. Rossetto O, Pirazzini M, Montecucco C. 2014. Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat Rev Microbiol 12:535–549. https://doi.org/10.1038/nrmicro3295.

6. Montecucco C, Schiavo G. 1994. Mechanism of action of tetanus and botulinum neurotoxins. Mol Microbiol 13:1–8. https://doi.org/10.1111/j.1365-2958.1994.tb00396.x.

7. Schiavo G, Rossetto O, Tonello F, Montecucco C. 1995. Intracellular targets and metallotargets of action of tetanus and botulinum neurotoxins. Curr Top Microbiol Immunol 195:257–274.

8. Gimenez DF, Gimenez JA. 1995. The typing of botulinum neurotoxins. Int J Food Microbiol 27:1–9. https://doi.org/10.1016/0168-1605(94)00144-U.

9. Dressler D, Bhidayasiri R, Bohlega S, Chana P, Chien HF, Chung TM, Colosimo C, Ebke M, Fedoroff K, Frank B, Kaji R, Kozaki S, Micheli F, Orlova O, Pellett S, Relja M, Rosales RL, Sagástegui-Colosimo C, Schoenen PW, Shahidi GA, Timerbaeva S, Walter U, Saberi FA. 2018. Defining spasticity: a new approach considering current movement disorders terminology and botulinum toxin therapy. J Neurol 265:856–862. https://doi.org/10.1007/s00415-018-8759-1.

10. Hill KK, Smith TJ, Helma CH, Ticknor LO, Foley BT, Svensson RT, Brown JL, Johnson EA, Smith LA, Okinaka RT, Jackson PJ, Marks JD. 2007. Genetic diversity among botulinum neurotoxin-producing clostridial strains. J Bacteriol 189:818–832. https://doi.org/10.1128/JB.01180-06.

11. Montecucco C, Rasotto MB. 2015. On botulinum neurotoxin variability. mBio 6:e02131-14. https://doi.org/10.1128/mBio.02131-14.

12. Smith TJ, Lou J, Geren IN, Forsyth CM, Tsai R, Laporte SL, Tepp WH, Bradshaw M, Johnson EA, Smith LA, Marks JD. 2005. Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect Immun 73:5450–5457. https://doi.org/10.1128/IAI.73.9.5450-5457.2005.

13. Henkel JS, Jacobson M, Tepp W, Pier C, Johnson EA, Barbieri JT. 2009. Catalytic properties of botulinum neurotoxin subtypes A3 and A4. Biochemistry 48:2522–2528. https://doi.org/10.1021/bi801666b.

14. Tepp WH, Lin G, Johnson EA. 2012. Purification and characterization of a novel subtype A3 botulinum neurotoxin. Appl Environ Microbiol 78:3108–3113. https://doi.org/10.1128/AEM.07967-11.

15. Pier CL, Chen C, Tepp WH, Lin G, Janda KD, Barbieri JT, Pellett S, Johnson EA. 2011. Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1. FEBS Lett 585:199–206. https://doi.org/10.1016/j.febslet.2010.11.045.

16. Whitmarsh RC, Tepp WH, Bradshaw M, Lin G, Pier CL, Scherf JM, Johnson EA, Pellett S. 2013. Characterization of botulinum neurotoxin A subtypes 1 through 5 by investigation of activities in mice, in neuronal cell cultures, and in *vitro*. Infect Immun 81:3894–3902. https://doi.org/10.1128/IAI.00536-13.

17. Pellett S, Tepp WH, Whitmarsh RC, Bradshaw M, Johnson EA. 2015. In vivo onset and duration of action varies for botulinum neurotoxin A subtypes 1–5. Toxicon 107:37–42. https://doi.org/10.1016/j.toxicon.2015.06.021.

18. Torii Y, Kiyota N, Sugimoto N, Mori Y, Goto Y, Harakawa T, Nakahira S, Kaji R, Kozaki S, Ginnaga A. 2011. Comparison of effects of botulinum toxin subtype A1 and A2 using twitch tension assay and rat grip strength test. Toxicon 57:93–99. https://doi.org/10.1016/j.toxicon.2015.09.009.

19. Torii Y, Goto Y, Nakahira S, Kozaki S, Kaji R, Ginnaga A. 2015. Comparison of systemic toxicity between botulinum toxin subtypes A1 and A2 in mice and rats. Basic Clin Pharmacol Toxicol 116:524–528. https://doi.org/10.1111/bcpt.12351.

20. Kaji R. 2015. Clinical differences between A1 and A2 botulinum toxin subtype A1 and A2 using twitch tension assay and rat grip strength test. Toxicon 57:93–99. https://doi.org/10.1016/j.toxicon.2015.09.009.

21. Morineaux V, Mazuet C, Hilaire D, Enche J, Popoff MR. 2015. Characterization of botulinum neurotoxins type A subtypes by immunocapture enrichment and liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem 407:5559–5570. https://doi.org/10.1007/s00216-015-8707-1.

22. Kull S, Schulz KM, Weismann J, Kirchner S, Schreiber T, Bollenbach A, Dabrowski PW, Nitsche A, Kalb SR, Dormer MB, Barr JR, Rummel A, Dormer...
23. Luquez C, Raphael BH, Maslanka SE. 2009. Neurotoxin gene clusters in Clostridium botulinum type Ab strains. Appl Environ Microbiol 75: 6094– 6101. https://doi.org/10.1128/AEM.01009-09.

24. Pellett S, Tepp WH, Bradshaw M, Kalb SR, Dykes JK, Lin G, Nawrocki EM, Pier CL, Barr JR, Maslanka SE, Johnson EA. 2016. Purification and characterization of botulinum neurotoxin FA from a genetically modified Clostridium botulinum strain. mSphere 1:e00100-15. https://doi.org/10.1128/mSphere.00100-15.

25. Marshall KM, Bradshaw M, Johnson EA. 2010. Conjugative botulinum neurotoxin-encoding plasmids in Clostridium botulinum. PLoS One 5:e11087. https://doi.org/10.1371/journal.pone.0011087.

26. Malizio CJ, Goodnough MC, Johnson EA. 2000. Purification of Clostridium botulinum type A neurotoxin. Methods Mol Biol 145:27–39. https://doi.org/10.1385/1-59259-052-7:27.

27. Jacobson MJ, Lin G, Tepp W, Dupuy J, Stenmark P, Stevens RC, Johnson EA. 2011. Purification, modeling, and analysis of botulinum neurotoxin subtype A5 (BoNT/A5) from Clostridium botulinum strain A661222. Appl Environ Microbiol 77:4217– 4222. https://doi.org/10.1128/AEM.00201-11.

28. Whitemarsh RC, Tepp WH, Johnson EA, Pellett S. 2014. Persistence of botulinum neurotoxin A subtypes 1–5 in primary rat spinal cord cells. PLoS One 9:e90252. https://doi.org/10.1371/journal.pone.0090252.

29. Lin G, Tepp WH, Pier CL, Jacobson MJ, Johnson EA. 2010. Expression of the Clostridium botulinum A2 neurotoxin gene cluster proteins and characterization of the A2 complex. Appl Environ Microbiol 76:40–47. https://doi.org/10.1128/AEM.01882-09.

30. Pellett S, Tepp WH, Toth SI, Johnson EA. 2010. Comparison of the primary rat spinal cord cell (RSC) assay and the mouse bioassay for botulinum neurotoxin type A potency determination. J Pharmacol Toxicol Methods 61:304–310. https://doi.org/10.1016/j.vascn.2010.01.003.

31. Whitemarsh RC, Strathman MJ, Chase LG, Stankewicz C, Tepp WH, Johnson EA, Pellett S. 2012. Novel application of human neurons derived from induced pluripotent stem cells for highly sensitive botulinum neurotoxin detection. Toxicol Sci 126:426 – 435. https://doi.org/10.1093/toxsci/kfr354.

32. Schantz PM, Glickman LT. 1978. Toxocaral visceral larva migrans. N Engl J Med 298:436 – 439. https://doi.org/10.1056/NEJM197802232980806.

33. McCroskey LM, Hatheway CL. 1988. Laboratory findings in four cases of adult botulism suggest colonization of the intestinal tract. J Clin Microbiol 26:1052–1054.

34. Pellett S, Tepp WH, Clancy CM, Borodic GE, Johnson EA. 2007. A neuronal cell-based botulinum neurotoxin assay for highly sensitive and specific detection of neutralizing serum antibodies. FEBS Lett 581:4803– 4808. https://doi.org/10.1016/j.febslet.2007.08.078.

35. Reed LJ, Muench H. 1938. A simple method of estimating fifty per cent endpoints. Am J Hyg 27:493– 497. https://doi.org/10.1093/oxfordjournals.aje.a118408.